Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

Oppenheimer analyst Les Sulewski has initiated coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) with an Outperform rating. The analyst has set a price target of $10 for the company's stock.